Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.

 

Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.

 

Annual Report

MorphoSys recently published its 2012 Annual Report and the Online Magazine with additional information.

 

News

  • 13/05/2013 // MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma

    more …

  • 10/05/2013 // MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

    more …

Find more releases in the news overview

100 bn. antibodies

MorphoSys latest antibody platform Ylanthia now commercially available for partners.

 

Media & Investors

The latest company news for media representatives and the financial community.